NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Sponsor: Biogen. Phase: PHASE2. Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia